ProteoGenix :: Innovative clinical genomic and proteomic technologies to the focused mission of developing and marketing diagnostic tests during a woman’s pregnancy.

ProteoGenix At A Glance

Founded in 2002
ProteoGenix is first company to identify and map more than 800 unique proteins in the proteome of pregnancy
Winner of the Best Clinical Study Award, 2007 Society for Maternal-Fetal Medicine
ProteoGenix’ Vision: the application of highly accurate nucleic acid-based technologies and unique biomarkers to develop and commercialize effective, non-invasive diagnostics that allow more accurate identification and treatment of significant maternal, fetal and neonatal complications such as intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia and Down syndrome
Introducing ProteoGenix CLIA-certified Clinical Laboratory: focused on advancing maternal/fetal/neonatal diagnostic medicine by providing innovative, highly effective diagnostic tests for more accurate identification of significant complications of pregnancy
Investors: New Leaf Venture Partners, TPG Biotechnology, Burrill & Company, Kaiser Permanente Ventures
Founded in 2002
ProteoGenix is first company to identify and map more than 800 unique proteins in the proteome of pregnancy
Winner of the Best Clinical Study Award, 2007 Society for Maternal-Fetal Medicine
ProteoGenix’ Vision: the application of highly accurate nucleic acid-based technologies and unique biomarkers to develop and commercialize effective, non-invasive diagnostics that allow more accurate identification and treatment of significant maternal, fetal and neonatal complications such as intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia and Down syndrome
Introducing ProteoGenix CLIA-certified Clinical Laboratory: focused on advancing maternal/fetal/neonatal diagnostic medicine by providing innovative, highly effective diagnostic tests for more accurate identification of significant complications of pregnancy
Investors: New Leaf Venture Partners, TPG Biotechnology, Burrill & Company, Kaiser Permanente Ventures
Founded in 2002
ProteoGenix is first company to identify and map more than 800 unique proteins in the proteome of pregnancy
Winner of the Best Clinical Study Award, 2007 Society for Maternal-Fetal Medicine
ProteoGenix’ Vision: the application of highly accurate nucleic acid-based technologies and unique biomarkers to develop and commercialize effective, non-invasive diagnostics that allow more accurate identification and treatment of significant maternal, fetal and neonatal complications such as intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia and Down syndrome
Introducing ProteoGenix CLIA-certified Clinical Laboratory: focused on advancing maternal/fetal/neonatal diagnostic medicine by providing innovative, highly effective diagnostic tests for more accurate identification of significant complications of pregnancy
Investors: New Leaf Venture Partners, TPG Biotechnology, Burrill & Company, Kaiser Permanente Ventures
Founded in 2002
ProteoGenix is first company to identify and map more than 800 unique proteins in the proteome of pregnancy
Winner of the Best Clinical Study Award, 2007 Society for Maternal-Fetal Medicine
ProteoGenix’ Vision: the application of highly accurate nucleic acid-based technologies and unique biomarkers to develop and commercialize effective, non-invasive diagnostics that allow more accurate identification and treatment of significant maternal, fetal and neonatal complications such as intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia and Down syndrome
Introducing ProteoGenix CLIA-certified Clinical Laboratory: focused on advancing maternal/fetal/neonatal diagnostic medicine by providing innovative, highly effective diagnostic tests for more accurate identification of significant complications of pregnancy
Investors: New Leaf Venture Partners, TPG Biotechnology, Burrill & Company, Kaiser Permanente Ventures